Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination.
Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination.
复制标题
DOI：
10.1155/2021/3619131
复制
发表时间：
2021
影响因子：
1.1
通讯作者：
Finsterer J
中科院分区：
文献类型：
--
作者：
Finsterer J
自引入基于mRNA技术和基于载体的COVID-19疫苗以来，偶尔会报告对这些药物的不良反应。尚未通报接种COVID-19疫苗后不久格林-巴利综合征（GBS）加重的情况。该患者是一名32岁的男性，在首次接种基于载体的疫苗后8天出现进行性感觉障碍和肌肉无力。脑脊液检查显示细胞蛋白分离，神经传导研究显示脱髓鞘。静脉注射免疫球蛋白（IVIG）对感觉和运动缺陷仅具有边际效应。此外，患者的病史为14年前具有显著运动缺陷的先前GBS阳性，其对IVIG反应良好，导致在康复后9个月内几乎完全恢复。尽管显然极为罕见，但神经科医生应保持警惕，以防接种基于载体的COVID-19疫苗后GBS复发。
Since the introduction of mRNA technology-based and vector-based COVID-19 vaccines, adverse reactions to these agents have been occasionally reported. Exacerbation of Guillain–Barré syndrome (GBS) shortly after COVID-19 vaccination has not been communicated. The patient is a 32-year-old male who developed progressive sensory disturbances and muscle weakness 8 days after the first dosage of a vector-based vaccine. Cerebrospinal fluid investigations revealed a dissociation cyto-albuminque, and nerve conduction studies revealed demyelination. Intravenous immunoglobulin (IVIG) exhibited only a marginal effect for both sensory and motor deficits. The patient's history was moreover positive for previous GBS with marked motor deficits 14 years earlier, which responded favourably to IVIG leading to almost complete recovery within 9 months of rehabilitation. Although apparently extremely rare, neurologists should remain vigilant for a potential recurrence of GBS after vaccination with a vector-based COVID-19 vaccine.